Rise.
Libido, sexual function, and central arousal pathways.
A 14-week sexual health arc built on PT-141 (Bremelanotide), a melanocortin receptor agonist that acts centrally — through the brain — rather than vascularly. Rise addresses arousal and desire in both men and women without affecting blood pressure or vascular tone the way PDE5 inhibitors do.
What's in the vial.
A cyclic heptapeptide derived from alpha-MSH. FDA-approved (under the brand Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
Activates MC4R receptors in the hypothalamus, increasing dopaminergic tone in arousal pathways. Effects are mediated through the central nervous system, not the vasculature.
What patients report.
- →Increased sexual desire and arousal in both sexes
- →Onset within 30–60 minutes of administration
- →Effective independent of vascular function
- →No interaction with nitrates or PDE5 inhibitors
- →Use as needed, not daily
Designed for.
- Adults experiencing low libido or arousal
- Patients for whom PDE5 inhibitors are contraindicated or insufficient
- Couples addressing desire discrepancy with provider guidance
How the arc unfolds.
- 01 · Wk 1–2
Provider-supervised initial dose, tolerance check.
- 02 · Wk 3–10
As-needed dosing with structured journaling.
- 03 · Wk 11–14
Reassessment and dose individualization.
Average outcomes.
Aggregated from Protokol partner-clinic submissions. Individual results vary.
Other protocols.
Begin Rise.
Every Protokol arc starts with a partner clinician — bloodwork, supervision, and follow-up included.
Start Your Journey →